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Discussion and Conclusions 
Cell productions were feasible but the quality of the initial muscle biopsy is important. Cell administrations were feasible and clinically well tolerated by all patients but one. The 
control of local cell distribution may be improved by echographic monitoring. Results show slight increases in twitch response and slight decrease in fatigue in the 3rd group. The 
combination of cell type (myoblasts) and of the modality (dense multisite injections) may have positively affected the TA muscle, BUT: No clinically significant gain of function perceived 
by FSHD patients, and no significant changes were noted at MRI and PET-Scan.The local FSHD1 degenerated muscle environment may be detrimental to the stability of the fibers or of 
the niches, and muscle regeneration may have been inefficient, too transitory, aborted or too unstable. 
The  slight muscle strength increase may not be clinically significant for FSHD patients, but may improve the quality of life of patients with more advanced muscle loss (e.g. DMD 
patients) in other indications.  
Introduction 
Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is one of the most 
frequent adult myopathies (1/20.000), with selective involvement of specific 
groups of muscles : facial, scapular fixator, anterior foreleg muscles, abdominal 
and humeral muscles.  
Vastus lateralis (VL) is usually spared clinically until late stages of the disease, 
and myoblasts grown from VL have similar behaviour in vivo and in vitro than 
myoblasts from control patients 
 
-> Proposal: 
Transplantation of autologous myoblast from spared muscle (VL) into an 
affected muscle as the Tibialis anterior (TA) muscle could locally improve the 
muscle’s regenerative capacities.  
Clinically 
spared 
Clinically 
affected 
Purpose of the study 
Primary endpoints: Safety, feasability 
- Feasability of cell preparation 
- Safety of intramuscular injections of cells 
- Clinical and biological tolerance of cell transplantation 
 
Secondary endpoints : Follow-up of muscle strength and 
resistance to fatigue over 2 years 
- Mechanical testing of strength and resistance to fatigue 
- Surface electromyography, MRI and FDG fixation by PET-Scan 
 
Specific inclusion criteria  
- Men and women aged 18-65. 
- Clinical manifestations of DMFSH confirmed by molecular diagnosis (D4Z4 
repeats). 
- Lack of clinical deficit in at least one VL muscle (assessed by score at knee 
extension, MRC = 5), and absence of adipo-fibrotic invasion (assessed by 
MRI). 
- Motor deficiency of at least one anterior leg (assessed by score at foot 
dorsiflexion, MRC < 4) and fatty infiltration in at least one TA muscle 
(assessed by MRI).  
 
-> Three groups of at least three patients selected in a sequential fashion.  
Clinical parameters 
Informations collected repeatedly from early (D0) to late phases (1mo).  
Clinical monitoring: overall wellness, heart rate and pressure, fever, 
cutaneous status, pain, redness, edema… 
Biological monitoring: blood formulation, sedimentation, inflammation 
(CRP), CPK, myoglobinemia, myoglobinuria, creatininemia, ions, calcemia, 
phosphoremia, transaminases, transferases.  
1-2g of VL muscle harvested under local anaesthesia in Nice Hospital and 
shipped to the Saint Louis Cell Therapy Laboratory in Paris. Within 24h, 
biopsies minced, digested, filtered and cells grown in a myogenic proprietary 
medium. Cells settled and expanded on days 8, 11, 14, 17, 20/21. 
Phenotypical characterization (CD56 NCAM), viability, microbiological 
controls, endotoxins assessed according to classical procedures. 
Methodologies, products and clinical protocols validated by regulatory 
agencies.  
Cell cultures 
Biopsy 
Culture Observation 
Mincing 
Autologous cell transplantations 
800 million cells containing >50% CD56+ cells concentrated in an isotonic 
saline buffer. 
Injection of cells suspended in 10ml, into half of TA muscle (surface: 
approx. 20 cm2 ; volume: approx. 40 cm3). 
3 groups of patients : 3 injection modalities with increased densities of 
needle trajectories per surface unit :  
-> Group 1 : 64 sites, interspace 5 mm – Group 2 : 100 sites, interspace 4 
mm – Group 3: 189 sites, interspace 3mm.  
 
  
 
Harvest 800x106 
MMT testing and Electromyography 
Global manual testing performed at time of inclusion, then at 15 d, 21 d, 1, 
2, 3, 4, 5, 6, 12 months. Measurement of dorsal and plantar flexion of 
ankles, extension and flexion of knees, abduction and antepulsion of 
shoulders, extension and flexion of arms.  
Maximal voluntary contraction (MVC) of ankle dorsiflexor muscles were 
measured with an ankle dynamometer (isometric strength).  
Fatiguing exercise consisted in a maximal isometric dorsiflexion lasting 30 s. 
A fatigue index (FI) was determined. 
Muscle activity of TA muscle was recorded by bipolar sEMG electrodes (10 
mm diameter, 20 mm inter-electrode distance). 
Common peroneal nerve stimulation was induced with a constant-current 
stimulator to evoke the electrophysiological and associated mechanical 
responses. The peak-to-peak amplitudes of the three Mmax responses of 
the TA muscle and the maximal amplitude of the three mechanical twitches 
(Pt) elicited by single stimuli at rest were averaged. The root mean square 
(RMS) of the sEMG recordings of the TA muscle was analyzed over a 500ms 
period around the peak force.  
 
 
 
PET-Scan analysis 
18F-fluorodéoxyglucose (18FDG) accumulates in some tissues as a function 
of their metabolic activity, especially in brain, myocardium and skeletal 
muscle upon exercise.  
Measurements have been done at the level of TA upon standardized 
exercise before implantation, then 3 and 6 months later to quantify the 
volumes of metabolically active muscle tissue.  
 
NMR imagery 
At inclusion, absence of fatty infiltration in one VL (donor muscle) and the 
presence of abnormal fatty infiltration in one TA (recipient muscle) are 
documented without Gadolinium. 
Graded semi-quantitative analysis expressing the ratio fat signal / skeletal 
muscle signal obtained by NMR imaging using Gadolinium contrast agent and 
T1 ponderation done before, 1, 3 and 6 months after implantation to evaluate 
the inflammatory reaction and the evolution of the volume of fatty infiltration 
(at middle and lower parts of the thigh and of the leg).  
Patient characteristics  
 Patient  
 Age at 
inclusion  
 Duration of 
disease at 
inclusion  
 Number of 
D4Z4 repeats  
 Global 
Sumscore at 
inclusion 
(/80)  
 Tibialis MMT 
score at 
inclusion  
 Quadrcieps 
MMT score at 
inclusion  
 FSHD1  54  9  6  62,99 2 5 
 FSHD2  51  16  7  64,66 3+ 5 
 FSHD3  49  16  6  65,68 2- 5 
 FSHD4  44  23  7  61,33 1 5 
 FSHD5  60  10  7  62,65 2+ 5 
 FSHD6  48  32  7  70,00 3- 5 
 FSHD7  52  15  7  65,33 1+ 5 
 FSHD8  59  2  7  74,33 3- 5 
 FSHD9  64  15  6  73,33 4+ 5 
 FSHD10  61  20  8  65,69 3- 5 
 FSHD11  59  8  9  63,33 2 5 
Mean +/- SD 55 +/- 6,4 15 +/- 8,1   66,3 +/- 4,3     
Description of patients Results of Cell cultures 
Cell culture feasibility 
Patient 
Biopsy  
Culture 
duration 
(days) 
Final number 
of cells 
(millions) 
Final CD56 
(%) 
Viability (%) 
Microbiologic
al controls / 
Endotoxins 
Feasibility 
Weight (g) 
Initial 
number of 
cells (106) 
 FSHD1  1,7 1,58 22 1238 96,2 93,4 Neg / Neg Good 
 FSHD2  1,9 0,95 20 1937 98,2 92,5 Neg / Neg Good 
 FSHD3  1,9 0,68 20 993 94,1 95,6 Neg / Neg Good 
 FSHD4  1,1 0,71 21 999 92 93,2 Neg / Neg Good 
 FSHD5  1,9 0,9 22 1357 71,3 92,5 Neg / Neg Good 
 FSHD6  1,4 2,55 21 2037 50,05 91,45 Neg / Neg Good 
 FSHD7  1,7 0,85 21 1767 63,6 98,1 Neg / Neg Good 
 FSHD8  1,1 0,28 21 1081 25,3 * 97 
Neg / Not 
Done 
Not grafted / 
Not reached 
 FSHD9  1,2 2,09 21 2000 18,3 * 96,4 
Neg / Not 
Done 
Not grafted / 
Not reached 
 FSHD10  1,6 1,26 28 804,5 95,94 95,7 Neg / Neg Good 
 FSHD11  2 0,38 20 1855 97,63 97,8 Neg / Neg Good 
Inter-individual variabilities may be important. CD56+ cut-off reached 9 times out 
of 11 within three weeks. In two cases, biopsies looked fibro-adipocytic, purity was 
not reached. Muscle biopsy were then extemporaneously qualified using histology.  Clinical outcomes 
Clinical tolerance  
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Final 
tolerance 
 FSHD1  
Y (< 50 
mm) 
N N N N N N 
Y (clinically 
not 
significant) 
N Y Good 
 FSHD2  ND ND N N N N N N N Y Good 
 FSHD3  
Y (< 50 
mm) 
ND N N N N N N N Y Good 
 FSHD4  N N N N N N N N N Y Good 
 FSHD5  N ND N N N N N N N Y Good 
 FSHD6  N ND N N N N N N N Y Good 
 FSHD7  N N N N N N N 
Y (CRP 
160,2) 
AN Y Questionable 
 FSHD10  N N N N N N N 
Y (clinically 
not 
significant) 
N Y Good 
 FSHD11  N ND N N N N N N N Y Good 
Mean differential MMT in each methodological series 
  Serie 1 Serie 2 Serie 3 
  
∆Treated ∆Untreated 
Global 
∆Sumscore 
∆Treated ∆Untreated 
Global 
∆Sumscore 
∆Treated ∆Untreated 
Global 
∆Sumscore 
M1 -19,97% -6,79% -17,51% 6,31% 0,00% -0,94% 23,71% 0,00% -1,88% 
M3 -13,31% -2,59% -11,48% 17,31% 0,00% -1,28% 23,71% 0,00% -2,24% 
M6 -16,62% -9,38% -10,16% 17,31% 0,00% -2,32% 19,79% 0,00% -1,74% 
M9 -22,12% -9,38% -8,09% 17,31% -1,33% -2,35% 18,21% -8,27% 0,23% 
M12 -15,51% -9,38% -7,65% 28,64% -1,33% -1,86% 15,44% -13,37% -2,07% 
The maximal voluntary isometric strength of the dorsiflexor muscles remained 
constant during the follow-up period. The fatigue index of the dorsiflexor muscles 
of the experimental leg tend to decrease over the 12 months whereas the one from 
the control leg fluctuated. 
The neuromuscular transmission was preserved after the cell therapy. The 
mechanical twitch response of the dorsiflexor muscles of the experimental leg 
slightly increased over the follow-up period.  
Taken together, and considering that no changes were observed on the control leg, 
these results lead us to conclude that the cell therapy may have positively affected 
the experimental leg. 
MMT and Electromyography 
PET-Scan evolution 
No significant changes were noted over the follow-up period.  
Multisite injection 
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